Early trial tests PRX3-targeting treatment for relapsed mesothelioma

Mesothelioma is most often associated with asbestos exposure and remains difficult to control after relapse. The reported results matter because they pair a clinical safety assessment with evidence that the proposed mechanism occurred in patient tissue, rather than relying only on cell or animal work. If later trials confirm benefit, PRX3 inhibition could add a treatment approach distinct from simply increasing antioxidant activity. The same mechanism is also being investigated for peritoneal malignancies, gastric cancer and other gastrointestinal cancers, although those possible uses remain research questions.

Mesothelioma is described in the source as a rare, aggressive cancer most often linked to asbestos exposure. It reports about 30,000 diagnoses worldwide each year, median survival of about 12 months and an approximately 10% five-year survival rate. Chemotherapy and immunotherapy can help some patients, but the source says treatment options remain limited. The PRX3 approach is based on a feature shared by many cancer cells: high reactive-oxygen-species production associated with active metabolism. Rather than adding antioxidants, the research attempts to inhibit an antioxidant defense on which tumor cells may depend. The investigators report that PRX3 deletion did not produce an adverse phenotype in healthy mice, but that observation does not by itself establish long-term safety in people.

The University of Vermont work began around 2015, and RS Oncology was formed to move the findings toward clinical testing; the company sponsored the phase-one trial. The evidence is still preliminary: the cited clinical cohort included 15 patients, phase one primarily evaluates dose, safety and tolerability, and the source does not provide a randomized comparison with standard treatment. Although disease control and survival observations are encouraging, average progression-free survival was described as roughly comparable to existing treatments. The durability of any survival effect, fuller adverse-event data and which patients benefit most remain unresolved.

Researchers expect to present completed phase-two results at a global oncology meeting in 2026. Readers should look for participant numbers, comparator details if any, survival endpoints, adverse events and whether the earlier evidence of PRX3 target engagement is reproduced.